Eiger BioPharmaceuticals, Inc.

With new data presented at the recent European Association for the Study of the Liver meeting, Gilead is ready to seek US approval of its hepatitis D therapy bulevirtide once again. The firm had been

Japanese gene therapy venture AnGes, Inc. has decided to withdraw an application for the full approval in Japan of its hepatocyte growth factor (HGF) gene therapy Collategene (beperminogene perplasm

Amylyx Pharmaceuticals, Inc. is rebuilding after a major setback earlier this year when its sole commercial drug, Relyvrio (sodium phenylbutyrate/taurursodiol) for amyotrophic lateral sclerosis (ALS)

Japanese gene therapy venture AnGes, Inc. has decided to withdraw an application for the full approval in Japan of its hepatocyte growth factor (HGF) gene therapy Collategene (beperminogene perplasm